tadalafil has been researched along with Connective Tissue Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Blair, C; Coghlan, JG; Kuwana, M; Langley, J; Takahashi, T | 1 |
| Cleveland, JM; Minai, OA; Rao, Y; Rose, JA; Tonelli, AR | 1 |
| Dardi, F; Denton, CP; Esler, A; Galiè, N; Harmon, C; Li, B; Manes, A; Mazzanti, G; Palazzini, M; Varanese, L | 1 |
2 trial(s) available for tadalafil and Connective Tissue Diseases
| Article | Year |
|---|---|
Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
Topics: Adult; Comorbidity; Connective Tissue Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Phenylpropionates; Proportional Hazards Models; Pulmonary Arterial Hypertension; Pyridazines; Risk Assessment; Scleroderma, Systemic; Tadalafil; Treatment Outcome; Vasodilator Agents | 2020 |
Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
Topics: Connective Tissue Diseases; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Physical Examination; Tadalafil; Treatment Outcome; Vasodilator Agents | 2017 |
1 other study(ies) available for tadalafil and Connective Tissue Diseases
| Article | Year |
|---|---|
Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials.
Topics: Age Factors; Aged; Antihypertensive Agents; Connective Tissue Diseases; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Multivariate Analysis; Phenotype; Pulmonary Wedge Pressure; Randomized Controlled Trials as Topic; Tadalafil; Treatment Outcome; Vasodilator Agents; Walk Test | 2016 |